It was shown that an antibody against CD52 can effectively deplete CD52-expressing cells for the treatment of multiple sclerosis (a humanized monoclonal antibody called Alemtuzumab is used) [46] or in a mouse model (experimental autoimmune encephalomyelitis) [47]. This evidence concerns the gene CD52 and experimental autoimmune encephalomyelitis.